Loading organizations...
Stämm develops a novel high-throughput bioprocessor, leveraging a modular microfluidic platform to redefine biomanufacturing. This innovative system aims to create scalable, automated, and continuous production of biologics and cell therapies. By integrating microfluidics, electroporation, and robotics, Stämm provides advanced solutions designed to replace traditional large-scale bioreactors with more efficient, decentralized alternatives.
The company was founded in 2014 by Yuyo Llamazares Vegh and Federico D'Alvia Vegh. Their founding insight centered on the need to reinvent bioreactor technology, moving beyond the limitations of conventional systems to enable more accessible, repeatable, and sustainable bioproduction. They envisioned a future where the complexities of biomanufacturing could be streamlined through advanced engineering.
Currently, Stämm’s solutions are primarily utilized within Research-Use Only applications, supporting the development of critical biological substances. The long-term vision is to unlock the full potential of biotechnology by making biomanufacturing processes universally easy, scalable, and repeatable, thus accelerating innovation and the production of transformative therapies across the industry.
Stämm has raised $17.0M across 1 funding round.
Stämm has raised $17.0M in total across 1 funding round.
Stämm has raised $17.0M across 1 funding round. Most recently, it raised $17.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2022 | $17M Series A | Philip Broenniman | Mayfield, SOSV, Decarbonization Consortium, Dragones VC, Draper Associates, Draper Cygnus, Grid Exponential, NEW Abundance, Serenity Traders, Teramips, Trillian, Vistaenergy, Vista Equity Partners | Announced |
Stämm has raised $17.0M in total across 1 funding round.
Stämm's investors include Philip Broenniman, Mayfield, SOSV, Decarbonization Consortium, Dragones VC, Draper Associates, Draper Cygnus, Grid Exponential, New Abundance, Serenity Traders, Teramips, Trillian.
Stämm is a biotechnology company that develops advanced biomanufacturing solutions, specializing in automated, continuous production processes for biologics, cell therapies, and emerging applications like cultivated meat.[1][5][6] It serves biotech firms, pharma companies, and food-tech innovators by providing scalable bioreactors, cell line development, and AI-driven analysis of multi-omic data, solving key bottlenecks in efficiency, scalability, and repeatability of bioprocesses.[1][3][4] With locations in Buenos Aires, San Francisco, and Switzerland, Stämm has shown strong growth momentum through Series A funding led by Varana Capital, partnerships like SuperMeat for cultivated meat, and third-party validations achieving record antibody production.[1][2]
Stämm was founded in 2013 by Yuyo and Federico, who began by brewing beer—a bioprocess using yeast cells—and identified inefficiencies in traditional bioprocessing methods that hindered scalability in health, food, and energy sectors.[2][4] Their idea evolved into a mission to revolutionize biomanufacturing, gaining early traction through selection for Singularity University's Global Innovation Program in 2016 and joining GridX accelerator as its first portfolio company.[2] Pivotal moments include opening a pilot-scale biofacility in Buenos Aires, raising a Series A round led by Varana Capital, validating prototypes at BioArk in Switzerland with top antibody yields, and expanding R&D there while partnering with SuperMeat in 2023 to enter food tech.[1][2]
Stämm stands out in biomanufacturing through these key strengths:
Stämm rides the wave of continuous biomanufacturing, a trend shifting from batch to perfusion processes to cut costs and boost yields amid rising demand for biologics, cell therapies, and alternative proteins.[1][6] Timing aligns with biotech's scaling challenges post-pandemic and the alternative protein market's projected $290B growth by 2035, where Stämm's tech lowers goods costs through efficient biomass production.[1] Market forces like AI-biotech convergence and sustainability pressures favor its nature-inspired, modular approach, influencing the ecosystem by enabling startups like SuperMeat to accelerate and bridging pharma with food tech via investor networks.[1][2]
Stämm is poised to dominate scalable biomanufacturing by expanding its Bioprocessor into food tech and beyond, leveraging Series A momentum for larger pilots and economic scaling studies.[1][2] Trends like AI-optimized processes and cultivated meat will propel growth, potentially evolving Stämm into a platform enabler for biotech's next wave of discoveries. As bioprocessing bottlenecks fade, Stämm's continuous revolution—born from beer brewing—will unlock biotechnology's full potential, transforming how we produce life-saving therapies and sustainable proteins.[5][6]
